Q32 Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Net Income	-112.96	-5.01	-95.76	-128.69	-103.92	-55.58	-29.99	-8.05
Depreciation & Amortization	2.64	2.6	9.54	8.9	6.32	1.29	0.68	0.24
Share-Based Compensation	7.32	13.05	17.25	13.25	7.64	2.62	0.28	0.16
Other Operating Activities	6.76	-124.31	-40.78	12.21	-1.4	9.1	35.51	-0.84
Operating Cash Flow	-96.23	-113.66	-109.75	-94.33	-91.36	-42.56	6.48	-8.48
Capital Expenditures	0.33	-1.29	-2.4	-3.73	-21.83	-24.94	-1.96	-1.99
Acquisitions	0	130	0	0	0	0	0	0
Change in Investments	101	-92	-48.39	208.63	-29.97	-96.85	-78.07	0
Other Investing Activities	-	-	-	-	-	-	-1.5	-0.28
Investing Cash Flow	101.33	36.72	-50.79	204.9	-51.8	-121.79	-81.53	-2.27
Share Issuance / Repurchase	0.18	0.6	52.17	53.09	158.21	150.99	-0.02	0.38
Other Financing Activities	-	-	-	-	-	-	115.25	-
Financing Cash Flow	0.18	0.6	52.17	53.09	158.21	150.99	115.23	0.38
Net Cash Flow	5.28	-76.35	-108.37	163.66	15.06	-13.36	40.18	-10.37
Free Cash Flow	-95.9	-114.95	-112.15	-98.07	-113.19	-67.5	4.52	-10.47
Free Cash Flow Margin	-8296.19%	-3583.10%	-330.13%	-3629.35%	-6794.18%	-1268.34%	-	-
Free Cash Flow Per Share	-29.85	-36.05	-36.52	-38.45	-48.38	-42.55	32.82	-99.19

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).